In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D Productivity at GSK? He CEDD, She CEDD

Executive Summary

Management endorsed GlaxoSmithKline's new R&D structure-the CEDDs-as an overwhelming success during the Big Pharma's December 2003 R&D day. But the analyst and investor communities weren't uniformly impressed. And fair enough: regardless of GSK's excitement and the storm of numbers and early stage results that promise a robust series of product launches, it's too early to judge the success of the CEDD experiment. A lot can go wrong between now and 2008, when the pipeline will ripen or rot.

You may also be interested in...



GSK Woes Raise Big Pharma R&D Question

GSK's various thwarted efforts to boost productivity through R&D revamps begs the question whether big pharma should be trying to do in-house discovery and early development at all.

GSK Tries to Mimic Real-World Biotech

Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.

GSK's Risk-Sharing Deals to Compete with In-House R&D

Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel